197 related articles for article (PubMed ID: 25125599)
21. Effector T cells driving monophasic vs. relapsing/remitting experimental autoimmune uveitis show unique pathway signatures.
von Toerne C; Sieg C; Kaufmann U; Diedrichs-Möhring M; Nelson PJ; Wildner G
Mol Immunol; 2010; 48(1-3):272-80. PubMed ID: 20727594
[TBL] [Abstract][Full Text] [Related]
22. [Translational research with experimental autoimmune uveoretinitis (EAU)].
Usui M
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):137-58; discussion 159. PubMed ID: 17402560
[TBL] [Abstract][Full Text] [Related]
23. Induction of antigen-specific Treg cells in treating autoimmune uveitis via bystander suppressive pathways without compromising anti-tumor immunity.
Chen Z; Zhang T; Kam HT; Qiao D; Jin W; Zhong Y; Zhou M; Zhou H; Chong WP; Chen W; Chen J
EBioMedicine; 2021 Aug; 70():103496. PubMed ID: 34280776
[TBL] [Abstract][Full Text] [Related]
24. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells.
Wang RX; Yu CR; Mahdi RM; Egwuagu CE
J Biol Chem; 2012 Oct; 287(43):36012-21. PubMed ID: 22936807
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of tetrandrine on bovine serum albumin-induced uveitis in rabbits.
Xiao J; Wu S; Wang Y; Li J; Zhang S
J Ocul Pharmacol; 1993; 9(2):151-6. PubMed ID: 8345287
[TBL] [Abstract][Full Text] [Related]
26. The immunopathogenesis of chronic and relapsing autoimmune uveitis - Lessons from experimental rat models.
Diedrichs-Möhring M; Kaufmann U; Wildner G
Prog Retin Eye Res; 2018 Jul; 65():107-126. PubMed ID: 29496590
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
[TBL] [Abstract][Full Text] [Related]
28. Longdan Xiegan Decoction alleviates experimental autoimmune uveitis in rats by inhibiting Notch signaling pathway activation and Th17 cell differentiation.
Yin X; Qiu Y; Li Z; Guo L; Wei H; Liu B; Zhou M; Li T; Wang L; Jiang W; Bi H; Guo D
Biomed Pharmacother; 2021 Apr; 136():111291. PubMed ID: 33493870
[TBL] [Abstract][Full Text] [Related]
29. Ly6C
Ko JH; Lee HJ; Jeong HJ; Oh JY
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):6-12. PubMed ID: 29056505
[TBL] [Abstract][Full Text] [Related]
30. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.
Cunningham MA; Austin BA; Li Z; Liu B; Yeh S; Chan CC; Anglade E; Velagaleti P; Nussenblatt RB
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):249-55. PubMed ID: 18708627
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye.
Ko JH; Lee HJ; Jeong HJ; Kim MK; Wee WR; Yoon SO; Choi H; Prockop DJ; Oh JY
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):158-63. PubMed ID: 26699483
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells.
Ke Y; Jiang G; Sun D; Kaplan HJ; Shao H
Clin Immunol; 2011 Mar; 138(3):311-20. PubMed ID: 21256812
[TBL] [Abstract][Full Text] [Related]
33. A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Adamus G; Karren LJ; Mooney J; Burrows GG
Ophthalmic Res; 2010; 44(1):24-33. PubMed ID: 20145422
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity.
Li H; Zhu L; Wang R; Xie L; Chen Y; Duan R; Liu X; Huang Z; Chen B; Li Z; Wang X; Su W
Invest Ophthalmol Vis Sci; 2021 Dec; 62(15):31. PubMed ID: 34967854
[TBL] [Abstract][Full Text] [Related]
35. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis.
Demir T; Gödekmerdan A; Balbaba M; Türkçüoglu P; Ilhan F; Demir N
Indian J Ophthalmol; 2006 Dec; 54(4):241-5. PubMed ID: 17090875
[TBL] [Abstract][Full Text] [Related]
36. A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis.
Diedrichs-Möhring M; Leban J; Strobl S; Obermayr F; Wildner G
Invest Ophthalmol Vis Sci; 2014 Dec; 56(2):1147-57. PubMed ID: 25515581
[TBL] [Abstract][Full Text] [Related]
37. High drug payload nanoparticles formed from dexamethasone-peptide conjugates for the treatment of endotoxin-induced uveitis in rabbit.
Yu X; Zhang R; Lei L; Song Q; Li X
Int J Nanomedicine; 2019; 14():591-603. PubMed ID: 30666116
[TBL] [Abstract][Full Text] [Related]
38. Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.
Fang CB; Zhou DX; Zhan SX; He Y; Lin Z; Huang C; Li J
PLoS One; 2013; 8(4):e62071. PubMed ID: 23626769
[TBL] [Abstract][Full Text] [Related]
39. Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent.
Liang D; Zuo A; Shao H; Chen M; Kaplan HJ; Sun D
J Immunol; 2014 Dec; 193(11):5498-505. PubMed ID: 25367119
[TBL] [Abstract][Full Text] [Related]
40. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
